Distribution practices aligned to EU GDP guidelines
Ergopharm has aligned its outbound distribution practices to the EU guidelines on good distribution practice, qualifying transport lanes and defining how temperature excursions are handled.
Good manufacturing practice ends at the loading dock; good distribution practice governs what happens afterwards, and a medicine that was made correctly can still arrive unfit. Lane qualification means understanding what a route actually does to a shipment — the ambient extremes, the transhipment points, the time on tarmac — and choosing packaging and monitoring accordingly.
“A medicine can be made perfectly and still arrive unfit. The lane is part of the process.”
Shipments carry temperature monitoring appropriate to the product and the lane, and any excursion is assessed against stability data before the consignment is released for sale by the receiving partner. An excursion is not automatically a rejection, but it is never a shrug.
Responsibilities on either side of the handover are set out in the quality agreement with each partner.
Key facts
- Framework
- EU GDP guidelines (2013/C 343/01)
- Lanes
- Qualified against real route conditions
- Monitoring
- Appropriate to product and lane
- Excursions
- Assessed against stability data before release
This notice describes Ergopharm’s own packaging and processes and how they follow published standards; it does not assert a specific national marketing approval.